Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Ranbaxy gets USFDA nod to market Sumatriptan tablets


      New Delhi: Drug maker Ranbaxy Laboratories said Tuesday it has received final approval of the US health watchdog to manufacture and market in the country Sumatriptan Succinate Tablets used for the treatment of migraine attacks.

      The company has received the Food and Drug Administration approval to manufacture and market Sumatriptan Succinate Tablets in the US in 25 mg and 50 mg strengths, Ranbaxy said in a statement.

      With this approval, Ranbaxy has expanded the product portfolio of Sumatriptan tablets as the company had already got the FDA nod to launch the drug in 100 mg strength.

      “We are pleased to receive this final approval for Sumatriptan Succinate Tablets 25 mg and 50 mg in addition to the 100 mg that was previously approved,” Ranbaxy Laboratories vice-president, trade sales, North America, Bill Winter said.

      The office of generic drugs, USFDA, has determined that the Ranbaxy formulations to be bio-equivalence and have same therapeutic effect as that of GlaxoSmithKline’s patented drug Imitrex, Ranbaxy said.

      Ranbaxy in January last year had said that it would launch the drug in December 2008 the 25 mg, 50 mg and 100 mg strengths of generic Imitrex in the US with an exclusivity period of 180 days after settling a patent litigation with GlaxoSmithKline (GSK).

      However, it was not able to launch the drug due to delay in getting approval from the USFDA.

      Industry estimates put total annual sales of Imitrex at around $1 billion, with the 100 mg strength tablets accounting for more than $650 million. The 25 mg and 50 mg strength of the drug has a market of around $350 million per annum in the US.

      Ranbaxy Pharmaceuticals Inc is a US-based wholly owned subsidiary of Ranbaxy Laboratories. Ranbaxy Pharmaceuticals is engaged in the sale and distribution of generic and branded prescription products in the US heathcare system, the filing added.

      August 25, 2009


      Share this Article!

    Back to top^